Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Awaiting development [GID-TA10779] Expected publication date: TBC
Search results
221 results
-
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Awaiting development [GID-TA10778] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Awaiting development [GID-TA10718] Expected publication date: TBC
-
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4034]
Awaiting development [GID-TA10925] Expected publication date: TBC
-
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Awaiting development [GID-TA10926] Expected publication date: TBC
-
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]
Awaiting development [GID-TA10927] Expected publication date: TBC
-
Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia [ID4042]
Awaiting development [GID-TA10928] Expected publication date: TBC
-
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Awaiting development [GID-TA10929] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID4044]
Awaiting development [GID-TA10930] Expected publication date: TBC
-
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable [ID4045]
Awaiting development [GID-TA10931] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Awaiting development [GID-TA10933] Expected publication date: TBC
-
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]
Awaiting development [GID-TA10934] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Awaiting development [GID-TA10935] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Awaiting development [GID-TA10814] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Awaiting development [GID-TA10668] Expected publication date: TBC
-
Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer [ID3968]
Awaiting development [GID-TA10850] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]
Awaiting development [GID-TA10851] Expected publication date: TBC
-
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]
Awaiting development [GID-TA10773] Expected publication date: TBC
-
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Awaiting development [GID-TA10905] Expected publication date: TBC
-
Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949]
Awaiting development [GID-TA10907] Expected publication date: TBC
-
Pralsetinib for thyroid cancer [ID4018]
Awaiting development [GID-TA10910] Expected publication date: TBC
-
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]
Awaiting development [GID-TA10911] Expected publication date: TBC
-
Isatuximab in combination for newly diagnosed multiple myeloma [ID3981]
Awaiting development [GID-TA10912] Expected publication date: TBC
-
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Awaiting development [GID-TA10726] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]
Awaiting development [GID-TA10757] Expected publication date: TBC
-
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]
Awaiting development [GID-TA10916] Expected publication date: TBC
-
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Awaiting development [GID-TA10917] Expected publication date: TBC
-
Elranatamab for treating refractory multiple myeloma after 3 standard therapies [ID4026]
Awaiting development [GID-TA10918] Expected publication date: TBC
-
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Awaiting development [GID-TA10919] Expected publication date: TBC
-
Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]
Awaiting development [GID-TA10920] Expected publication date: TBC
-
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [ID3970]
Awaiting development [GID-TA10862] Expected publication date: TBC
-
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]
Awaiting development [GID-TA10863] Expected publication date: TBC
-
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]
Awaiting development [GID-TA10867] Expected publication date: TBC
-
Belimumab with rituximab for treating systemic lupus erythematosus [ID3967]
Awaiting development [GID-TA10869] Expected publication date: TBC
-
Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965]
Awaiting development [GID-TA10870] Expected publication date: TBC
-
Spesolimab for treating acute generalised pustular psoriasis [ID3963]
Awaiting development [GID-TA10871] Expected publication date: TBC
-
Mirikizumab for previously treated moderately to severely active ulcerative colitis [ID3973]
Awaiting development [GID-TA10872] Expected publication date: TBC
-
Relugolix treating pain from endometriosis [ID3982]
Awaiting development [GID-TA10873] Expected publication date: TBC
-
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]
Awaiting development [GID-TA10880] Expected publication date: TBC
-
Infigratinib for cholangiocarcinoma [ID3992]
Awaiting development [GID-TA10882] Expected publication date: TBC
-
Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 3 years and older [ID3990]
Awaiting development [GID-TA10883] Expected publication date: TBC
-
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]
Awaiting development [GID-TA10885] Expected publication date: TBC
-
Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]
Awaiting development [GID-TA10891] Expected publication date: TBC
-
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Awaiting development [GID-TA10893] Expected publication date: TBC
-
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]
Awaiting development [GID-TA10297] Expected publication date: TBC
-
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]
Awaiting development [GID-TA10332] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Awaiting development [GID-TA10702] Expected publication date: TBC
-
Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]
Awaiting development [GID-TA10737] Expected publication date: TBC
-
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]
Awaiting development [GID-TA10937] Expected publication date: TBC
-
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587
Awaiting development [GID-TA10519] Expected publication date: TBC